

## Supplementary information

---

# Comprehensive multi-attribute method workflow for biotherapeutic characterization and current good manufacturing practices testing

---

In the format provided by the authors and unedited

## **Comprehensive multi-attribute method (MAM) workflow for biotherapeutic characterization and cGMP testing**

Silvia Millán-Martín<sup>1</sup>, Craig Jakes<sup>1,2</sup>, Sara Carillo<sup>1</sup>, Richard Rogers<sup>3</sup>, Da Ren<sup>4</sup>, Jonathan Bones<sup>1,2</sup>

<sup>1</sup>National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co., Dublin, A94 X099 Ireland

<sup>2</sup>School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland

<sup>3</sup>Umoja Biopharma, Seattle, WA USA

<sup>4</sup>Amgen Inc., Process Development, Thousand Oaks, CA 91320, USA

\*To whom correspondence should be addressed, email: Jonathan.bones@nibr.ie,


tel: +35312158100, fax: +35312158116

Supplementary Figure 1	Sequence coverage map of NISTmAb obtained using (a) in-solution tryptic digestion or (b) automated digestion
Supplementary Figure 2	Sequence coverage map of a chimeric IgG1 DP obtained using (a) in-solution tryptic digestion or (b) automated digestion
Supplementary Figure 3	BioPharma Finder software dashboard showing the created target peptide workbook during MAM discovery phase for chimeric IgG1 DP
Supplementary Figure 4	Chromeleon CDS properties component window for unmodified peptide WQQGNVFSC[Carboxymethylation]SVMHEALHNHYTQK, which is selected as a reference component to monitor M431+oxidation.
Supplementary Table 1	Summary of PTMs identified and quantified for NIST mAb for in-solution and automated trypsin digestion


Supplementary Figure 1. Sequence coverage map of NISTmAb obtained using (a) in-solution tryptic digestion or (b) automated digestion. The coloured bars show the identified peptides, with the numbers in the bars reflecting the retention time. The different colors indicate the peptide recovery in the MS1 scan: red >50%, orange >20% and yellow >10% represent good recovery. Green, >5%, light blue >2% and cyan >1% represent fair recovery and grey-white scale shows poor recovered peptides.

a)

NISTmAb HC




NISTmAb LC




b)

NISTmAb heavy chain




NISTmAb light chain




Supplementary Figure 2. Sequence coverage map of chimeric IgG1 DP obtained using (a) in-solution tryptic digestion or (b) automated digestion. The coloured bars show the identified peptides, with the numbers in the bars reflecting the retention time. The different colors indicate the peptide recovery in the MS1 scan: red >50%, orange >20% and yellow >10% represent good recovery. Green, >5%, light blue >2% and cyan >1% represent fair recovery and grey-white scale shows poor recovered peptides.

a)

Chimeric IgG1 DP Heavy Chain




Chimeric IgG1 DP Light Chain



b)

Chimeric IgG1 DP Heavy Chain




Chimeric IgG1 DP Light Chain



Supplementary Figure 3. BioPharma Finder software dashboard showing the created target peptide workbook during MAM discovery phase for chimeric IgG1 DP.

Level	Identification	Normalized ID	Peptide Sequence	Modification	Site	Normalized Site	Relative Quantification Group Number	Charge State Distribution	RT (min)	RT Start (min)	RT Stop (min)	Theoretical Mass	Protein Name
1	Peptide 1-Q1-K19 = 1976.1055m	Q1-K19 = 1976.1055m	QVQLQGPQAEIVKPGASIVK	None				1	3-3	37.34	37.00	37.35	1976.1055
2	Peptide 1-Q1-K19 = 1976.1055m(Q1)	Q1-K19 = 1976.1055m(Q1)+NH3 loss	QVQLQGPQAEIVKPGASIVK	NH3 loss	Q1	Q1		1	1-3	44.12	43.95	44.36	1959.0789
3	Peptide 2-Q1-K18 = 1823.9993m	Q1-K18 = 1823.9993m	QVLSQSPRAISASPGEEK	None				2	2-3	47.79	47.60	48.00	1823.9993
4	Peptide 2-Q1-K18 = 1823.9993m(Q1)	Q1-K18 = 1823.9993m(Q1)+NH3 loss	QVLSQSPRAISASPGEEK	NH3 loss	Q1	Q1		2	1-3	58.06	57.85	58.27	1806.9727
5	Peptide 1-5444-G450 = 659.3490m	S1-G7 = 659.3490m(G7-Lys)	SLSLSPG	Lys	G450	G7		3	1-2	26.66	26.37	26.86	787.4440
6	Peptide 1-5444-G450 = 659.3490m	S1-G7 = 659.3490m	SLSLSPG	None				3	1-2	34.61	34.45	34.79	659.3490
7	Peptide 1-G44-K63 = 2182.0331m	G1-K20 = 2182.0331m	GLEWGSAYPNQDTSYHNQK	None				4	2-4	60.27	60.02	60.60	2182.0331
8	Peptide 1-G44-K63 = 2182.0331m(N5)	G1-K20 = 2182.0331m(N12-Deamidation)	GLEWGSAYPNQDTSYHNQK	Deamidation	N55	N12		4	2-3	61.01	60.76	61.41	2182.0331
9	Peptide 1-G44-K63 = 2182.0331m(N5)	G1-K20 = 2182.0331m(N12-NH3 loss)	GLEWGSAYPNQDTSYHNQK	NH3 loss	N55	N12		4	2-3	61.65	61.47	61.84	2165.0065
10	Peptide 1-F279-K292 = 1676.7947m	F1-K14 = 1676.7947m(N12-Deamidation)	FNWYVDVEVHNAK	Deamidation	N290	N12		5	3-3	47.80	47.82	48.07	1677.7787
11	Peptide 1-F279-K292 = 1676.7947m	F1-K14 = 1676.7947m(N12-NH3 loss)	FNWYVDVEVHNAK	NH3 loss	N290	N12		5	2-3	49.73	49.60	49.93	1659.7682
12	Peptide 1-F279-K292 = 1676.7947m	F1-K14 = 1676.7947m	FNWYVDVEVHNAK	None				5	1-4	46.59	46.51	46.75	1676.7947
13	Peptide 1-F279-K292 = 1676.7947m	F1-K14 = 1676.7947m(N2-NH3 loss)	FNWYVDVEVHNAK	NH3 loss	N280	N2		5	3-3	50.92	50.82	51.07	1659.7682
14	Peptide 1-F279-K292 = 1676.7947m	F1-K14 = 1676.7947m(D6-H2O loss)	FNWYVDVEVHNAK	H2O loss	D284	D6		5	2-3	52.12	52.00	52.36	1655.7641
15	Peptide 1-V306-K321 = 1806.9992m	V1-K16 = 1806.9992m	VVSVLTVHQDWLNGK	None				6	1-3	64.90	64.79	65.26	1806.9992
16	Peptide 1-V306-K321 = 1806.9992m	V1-K16 = 1806.9992m(N14-Deamidation)	VVSVLTVHQDWLNGK	Deamidation	N319	N14		6	3-3	66.51	66.34	66.81	1807.9832
17	Peptide 1-V306-K321 = 1806.9992m	V1-K16 = 1806.9992m(N14-NH3 loss)	VVSVLTVHQDWLNGK	NH3 loss	N319	N14		6	2-4	67.82	67.80	68.29	1789.9727
18	Peptide 1-V306-K321 = 1806.9992m	V1-K16 = 1806.9992m	VVSVLTVHQDWLNGK	None				6	4-4	65.19	65.02	65.49	1806.9992
19	Peptide 1-G375-K396 = 2543.1241m	G1-K22 = 2543.1241m	GFYPSDAVWESNSGQPNVNYK	None				7	2-4	58.21	57.90	58.49	2543.1241
20	Peptide 1-G375-K396 = 2543.1241m	G1-K22 = 2543.1241m(N19-Deamidation)	GFYPSDAVWESNSGQPNVNYK	Deamidation	-N393	-N19		7	2-3	58.87	58.68	59.38	2544.1081
21	Peptide 1-G375-K396 = 2543.1241m	G1-K22 = 2543.1241m(N20-NH3 loss)	GFYPSDAVWESNSGQPNVNYK	NH3 loss	-N394	-N20		7	2-3	58.89	58.65	59.03	2526.0975
22	Peptide 1-G375-K396 = 2543.1241m	G1-K22 = 2543.1241m(N14-NH3 loss)	GFYPSDAVWESNSGQPNVNYK	NH3 loss	-N388	-N14		7	2-3	59.80	59.62	60.08	2526.0975
23	Peptide 1-C325-K330 = 735.3585m	C1-K6 = 735.3585m	CKVSNK	(Carboxymethylation)	(C325)	(C1)		8	1-3	2.94	2.89	3.00	735.3585
24	Peptide 1-C325-K330 = 735.3585m(N5)	C1-K6 = 735.3585m(N5-Deamidation)	CKVSNK	Deamidation, (Carboxymethylation)	N329, (C325)	N5, (C1)		8	2-3	3.87	3.78	3.99	736.3425
25	Peptide 1-V327-K330 = 446.2489m	V1-K4 = 446.2489m	VSNK	None				8	1-2	1.80	1.77	1.86	446.2489
26	Peptide 1-A24-K38 = 1790.8086m	A1-K15 = 1790.8086m(M11-Oxidation)	ASGYTFTSYNMHWVK	Oxidation	M34	M11		9	2-3	42.99	42.77	43.18	1806.8036
27	Peptide 1-A24-K38 = 1790.8086m	A1-K15 = 1790.8086m	ASGYTFTSYNMHWVK	None				9	1-4	49.05	48.94	49.28	1790.8086
28	Peptide 1-S75-R88 = 2677.1524m	S1-R24 = 2677.1524m(M7-Oxidation)	SSSTAMQLSSLTSEDSAVVYCAR	Oxidation, (Carboxymethylation)	M81, (C96)	M7, (C22)		10	2-3	54.90	54.77	54.99	2693.1473
29	Peptide 1-S75-R88 = 2677.1524m	S1-R24 = 2677.1524m(M7+Oxidation)	SSSTAMQLSSLTSEDSAVVYCAR	Oxidation, (Carboxymethylation)	M81, (C96)	M7, (C22)		10	2-3	55.09	54.99	55.24	2693.1473
30	Peptide 1-S75-R88 = 2677.1524m	S1-R24 = 2677.1524m	SSSTAMQLSSLTSEDSAVVYCAR	(Carboxymethylation)	(C96)	(C22)		10	2-4	57.84	57.79	58.30	2677.1524
31	Peptide 1-D253-K259 = 834.4269m	D1-R7 = 834.4269m(M4+Oxidation)	DTLMSR	Oxidation	M256	M4		11	1-2	26.33	26.19	26.46	850.4219

Supplementary Figure 4. Chromeleon CDS properties component window for unmodified peptide WQQGNVFSC[Carboxymethylation]SVMHEALHNNHYTQK, which is selected as a reference component to monitor M431+oxidation.



Supplementary Table 1. Summary of PTMs identified and quantified for NIST mAb for in-solution and automated trypsin digestion. Relative abundances are calculated based on triplicate analysis (n=3).

Modification	Sequence	Relative Abundance (n=3)	
		In-solution	Automated KF
HC N328+deamidation	VSNKALPAPIEK CKVSNK VSNK	0.30	0.52
HC~N387/N392+deamidation	GFYPSDIAVEWESNGQPENNYK	0.79	0.90
HC N387+succinimide	GFYPSDIAVEWESNGQPENNYK	2.06	0.59
HC M255+oxidation	DTLMISR	1.26	1.98
HC G450+Lys	SLSLPG	12.99	13.88
HC N300+A2G0F	EEQYNSTYR	39.60	39.01
HC N300+A2G1F	EEQYNSTYR	39.36	39.38
HC N300+A2G2F	EEQYNSTYR	8.73	8.91